Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature

Research output: Contribution to journalReviewResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{c70a62dbe0214c28adc67be906c6e8e1,
title = "Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation?: A systematic review of the literature",
abstract = "Chimerism analysis following hematopoietic stem cell transplantation (HSCT) for leukemia is routinely applied in parallel with quantification of minimal residual disease (MRD) to identify imminent relapse. In the past decades, new methods with a lower limit of detection compared to standard methods have been developed, so-called microchimerism analysis. Microchimerism analysis is fast, simple, applicable across pre-HSCT disease-type and can be applied on peripheral blood allowing frequent testing during follow-up. Monitoring of microchimerism in blood could replace repeated bone marrow analysis for MRD and allow earlier detection of imminent relapse or graft failure. Clinical studies in single center cohorts have shown conflicting but promising results. There is currently no consensus on the interpretation of microchimerism analysis and heterogeneity of studies remains a major obstacle for inter-study comparisons and meta-analysis in this field. We have conducted a systematic review of studies investigating associations between microchimerism and relapse of leukemia post-HSCT. We summarize current evidence and provide suggestions for future research.",
keywords = "Allogeneic hematopoietic cell transplantation, Childhood leukemia, Chimerism, Microchimerism, Relapse",
author = "Haugaard, {Anna Karen} and Josefine Kofoed and Masmas, {Tania Nicole} and Madsen, {Hans Ole} and Marquart, {Hanne Vibeke} and Carsten Heilmann and M{\"u}ller, {Klaus Gottlob} and Marianne Ifversen",
note = "Copyright {\textcopyright} 2020 Elsevier Ltd. All rights reserved.",
year = "2020",
month = nov,
doi = "10.1016/j.blre.2020.100673",
language = "English",
volume = "44",
pages = "100673",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",

}

RIS

TY - JOUR

T1 - Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation?

T2 - A systematic review of the literature

AU - Haugaard, Anna Karen

AU - Kofoed, Josefine

AU - Masmas, Tania Nicole

AU - Madsen, Hans Ole

AU - Marquart, Hanne Vibeke

AU - Heilmann, Carsten

AU - Müller, Klaus Gottlob

AU - Ifversen, Marianne

N1 - Copyright © 2020 Elsevier Ltd. All rights reserved.

PY - 2020/11

Y1 - 2020/11

N2 - Chimerism analysis following hematopoietic stem cell transplantation (HSCT) for leukemia is routinely applied in parallel with quantification of minimal residual disease (MRD) to identify imminent relapse. In the past decades, new methods with a lower limit of detection compared to standard methods have been developed, so-called microchimerism analysis. Microchimerism analysis is fast, simple, applicable across pre-HSCT disease-type and can be applied on peripheral blood allowing frequent testing during follow-up. Monitoring of microchimerism in blood could replace repeated bone marrow analysis for MRD and allow earlier detection of imminent relapse or graft failure. Clinical studies in single center cohorts have shown conflicting but promising results. There is currently no consensus on the interpretation of microchimerism analysis and heterogeneity of studies remains a major obstacle for inter-study comparisons and meta-analysis in this field. We have conducted a systematic review of studies investigating associations between microchimerism and relapse of leukemia post-HSCT. We summarize current evidence and provide suggestions for future research.

AB - Chimerism analysis following hematopoietic stem cell transplantation (HSCT) for leukemia is routinely applied in parallel with quantification of minimal residual disease (MRD) to identify imminent relapse. In the past decades, new methods with a lower limit of detection compared to standard methods have been developed, so-called microchimerism analysis. Microchimerism analysis is fast, simple, applicable across pre-HSCT disease-type and can be applied on peripheral blood allowing frequent testing during follow-up. Monitoring of microchimerism in blood could replace repeated bone marrow analysis for MRD and allow earlier detection of imminent relapse or graft failure. Clinical studies in single center cohorts have shown conflicting but promising results. There is currently no consensus on the interpretation of microchimerism analysis and heterogeneity of studies remains a major obstacle for inter-study comparisons and meta-analysis in this field. We have conducted a systematic review of studies investigating associations between microchimerism and relapse of leukemia post-HSCT. We summarize current evidence and provide suggestions for future research.

KW - Allogeneic hematopoietic cell transplantation

KW - Childhood leukemia

KW - Chimerism

KW - Microchimerism

KW - Relapse

U2 - 10.1016/j.blre.2020.100673

DO - 10.1016/j.blre.2020.100673

M3 - Review

C2 - 32173088

VL - 44

SP - 100673

JO - Blood

JF - Blood

SN - 0006-4971

ER -

ID: 61695986